Skip to main content
Erschienen in: Supportive Care in Cancer 11/2012

01.11.2012 | Short Communication

High incidence of bloodstream infection detected by surveillance blood cultures in hematology patients on corticosteroid therapy

verfasst von: A. Joosten, J. Maertens, J. Verhaegen, T. Lodewyck, E. Vermeulen, K. Lagrou

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of our study was to evaluate the frequency of “occult” bacteremia/fungemia as well as the diversity of pathogens involved in hematology patients treated with corticosteroids.

Methods

Daily surveillance blood cultures were taken from patients treated with corticosteroids as part of their intensive chemotherapy or during graft-versus-host disease following hematopoietic stem cell transplantation during a 3-year period (2006–2009). We reviewed the frequency of occult bacteremia/fungemia as well as the pathogens involved.

Results

During the 3-year period, 3,821 bottles were cultured from 215 patients and 4.9 % of the bottles tested were positive. Surveillance blood cultures revealed bloodstream infection in 24 % of the patients (definite bloodstream infection in 16 %). Seventy-five percent of patients were still afebrile when microorganisms were detected. The main risk group was acute lymphocytic leukemia patients undergoing remission induction chemotherapy. The pathogens cultured most frequently were coagulase-negative staphylococci, enterococci, Escherichia coli, and Pseudomonas aeruginosa.

Conclusions

A high incidence of occult bacteremia was detected by surveillance blood cultures. Further studies are needed to evaluate if a strategy based on surveillance blood cultures can reduce mortality related to bloodstream infections.
Literatur
1.
Zurück zum Zitat Lin MY, Weinstein RA, Hota B (2008) Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 52:3188–3194PubMedCrossRef Lin MY, Weinstein RA, Hota B (2008) Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 52:3188–3194PubMedCrossRef
2.
Zurück zum Zitat Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB (1997) The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24:584–602PubMed Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB (1997) The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24:584–602PubMed
3.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93PubMedCrossRef
4.
Zurück zum Zitat O’Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, Masur H, American College of Critical Care Medicine, Infectious Diseases Society of America (2008) Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 36:1330–1349PubMedCrossRef O’Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, Masur H, American College of Critical Care Medicine, Infectious Diseases Society of America (2008) Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 36:1330–1349PubMedCrossRef
5.
Zurück zum Zitat Clinical and Laboratory Standards Institute (2007) Principles and procedures for blood cultures; approved guideline. CLSI document M47-A. Wayne, PA Clinical and Laboratory Standards Institute (2007) Principles and procedures for blood cultures; approved guideline. CLSI document M47-A. Wayne, PA
6.
Zurück zum Zitat Bailey JM (1991) New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors 3:97–102PubMed Bailey JM (1991) New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors 3:97–102PubMed
7.
Zurück zum Zitat Knudsen PJ, Dinarello CA, Strom TB (1987) Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 139:4129–4134PubMed Knudsen PJ, Dinarello CA, Strom TB (1987) Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 139:4129–4134PubMed
8.
Zurück zum Zitat Chizuka A, Kami M, Kanda Y, Murashige N, Kishi Y, Hamaki T, Kim SW, Hori A, Kojima R, Mori SI, Tanosaki R, Gomi H, Takaue Y (2005) Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 35:577–582PubMedCrossRef Chizuka A, Kami M, Kanda Y, Murashige N, Kishi Y, Hamaki T, Kim SW, Hori A, Kojima R, Mori SI, Tanosaki R, Gomi H, Takaue Y (2005) Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 35:577–582PubMedCrossRef
9.
Zurück zum Zitat Penack O, Keilholz U, Thiel E, Blau IW (2005) Value of surveillance blood cultures in neutropenic patients—a pilot study. Jpn J Infect Dis 58:171–173PubMed Penack O, Keilholz U, Thiel E, Blau IW (2005) Value of surveillance blood cultures in neutropenic patients—a pilot study. Jpn J Infect Dis 58:171–173PubMed
10.
Zurück zum Zitat Penack O, Rempf P, Eisenblatter M, Stroux A, Wagner J, Thiel E, Blau IW (2007) Bloodstream infections in neutropenic patients: early detection of pathogens and directed antimicrobial therapy due to surveillance blood cultures. Ann Oncol 18:1870–1874PubMedCrossRef Penack O, Rempf P, Eisenblatter M, Stroux A, Wagner J, Thiel E, Blau IW (2007) Bloodstream infections in neutropenic patients: early detection of pathogens and directed antimicrobial therapy due to surveillance blood cultures. Ann Oncol 18:1870–1874PubMedCrossRef
11.
Zurück zum Zitat Isenbergh HD (2007) Clinical microbiology procedures handbook. American Society of Microbiology Press (ASM), Washington Isenbergh HD (2007) Clinical microbiology procedures handbook. American Society of Microbiology Press (ASM), Washington
Metadaten
Titel
High incidence of bloodstream infection detected by surveillance blood cultures in hematology patients on corticosteroid therapy
verfasst von
A. Joosten
J. Maertens
J. Verhaegen
T. Lodewyck
E. Vermeulen
K. Lagrou
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1557-x

Weitere Artikel der Ausgabe 11/2012

Supportive Care in Cancer 11/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.